This page includes Regulatory news filings supplied by issuers listed on the BSX. Please note the BSX is not responsible for the content, accuracy or completeness of announcements filed by issuers and disclaims all liability for any loss arising from reliance on information contained within issuer announcements.
Jazz Pharmaceuticals to Report 2018 First Quarter Financial Results on 8 May 2018
Hamilton, Bermuda – 25 April 2018 – In a filing with the Bermuda Stock Exchange (“BSX”), Jazz Pharmaceuticals plc (Nasdaq: JAZZ) whose Secured Loan Notes are listed on the BSX announced that it will report its 2018 first quarter financial results on 8 May 2018. The full filing stated:
DUBLIN,April24,2018/PRNewswire/--JazzPharmaceuticalsplc(Nasdaq:JAZZ)todayannouncedthatitwillreportits2018firstquarterfinancialresultsonTuesday,May8,2018,afterthecloseofthefinancialmarkets.Companymanagementwillhostaliveaudiowebcastimmediatelyfollowingtheannouncementat4:30p.m.EDT/9:30p.m.ISTtodiscussfirstquarter2018financialresultsandprovideabusinessandfinancialupdate.
InterestedpartiesmayaccesstheliveaudiowebcastviatheInvestorssectionoftheJazzPharmaceuticalswebsiteathttp://www.jazzpharmaceuticals.com.Pleaseconnecttothewebsitepriortothestartoftheconferencecalltoensureadequatetimeforanysoftwaredownloadsthatmaybenecessarytolistentothewebcast.Areplayofthewebcastwillbearchivedonthewebsiteforatleastoneweek.
Audiowebcast/conferencecall:
U.S.Dial-InNumber:+18553537924InternationalDial-InNumber:+15033436056Passcode:9868758
AreplayoftheconferencecallwillbeavailablethroughMay15,2018andaccessiblethroughoneofthefollowingtelephonenumbers,usingthepasscodebelow:
ReplayU.S.Dial-InNumber:+18558592056
ReplayInternationalDial-InNumber:+14045373406
Passcode:9868758
AboutJazzPharmaceuticals
JazzPharmaceuticalsplc(Nasdaq:JAZZ)isaninternationalbiopharmaceuticalcompanyfocusedonimprovingpatients’livesbyidentifying,developingandcommercializingmeaningfulproductsthataddressunmetmedicalneeds.Thecompanyhasadiverseportfolioofproductsandproductcandidateswithafocusintheareasofsleepandhematology/oncology.Intheseareas,JazzPharmaceuticalsmarketsXyrem®(sodiumoxybate)oralsolution,Erwinaze®(asparaginaseErwiniachrysanthemi),Defitelio®(defibrotidesodium)andVyxeos®(daunorubicinandcytarabine)liposomeforinjectionintheU.S.andmarketsErwinase®andDefitelio®(defibrotide)incountriesoutsidetheU.S.Forcountry-specificproductinformation,pleasevisit http://www.jazzpharmaceuticals.com/products.Formoreinformation,pleasevisit http://www.jazzpharmaceuticals.com/andfollowusonTwitterat@JazzPharma.